ATE522515T1 - Modulatoren der dopamin-neurotransmission - Google Patents

Modulatoren der dopamin-neurotransmission

Info

Publication number
ATE522515T1
ATE522515T1 AT09738154T AT09738154T ATE522515T1 AT E522515 T1 ATE522515 T1 AT E522515T1 AT 09738154 T AT09738154 T AT 09738154T AT 09738154 T AT09738154 T AT 09738154T AT E522515 T1 ATE522515 T1 AT E522515T1
Authority
AT
Austria
Prior art keywords
modulators
dopamine neurotransmission
compounds
relates
neurotransmission
Prior art date
Application number
AT09738154T
Other languages
English (en)
Inventor
Clas Sonesson
Peder Svensson
Mikael Andersson
Original Assignee
Nsab Af Neurosearch Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nsab Af Neurosearch Sweden Ab filed Critical Nsab Af Neurosearch Sweden Ab
Application granted granted Critical
Publication of ATE522515T1 publication Critical patent/ATE522515T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AT09738154T 2008-04-29 2009-04-28 Modulatoren der dopamin-neurotransmission ATE522515T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200800600 2008-04-29
US4905708P 2008-04-30 2008-04-30
PCT/EP2009/055140 WO2009133110A1 (en) 2008-04-29 2009-04-28 Modulators of dopamine neurotransmission

Publications (1)

Publication Number Publication Date
ATE522515T1 true ATE522515T1 (de) 2011-09-15

Family

ID=40937591

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09738154T ATE522515T1 (de) 2008-04-29 2009-04-28 Modulatoren der dopamin-neurotransmission

Country Status (10)

Country Link
US (1) US8492372B2 (de)
EP (1) EP2271638B1 (de)
JP (1) JP5548853B2 (de)
CN (1) CN102015674B (de)
AT (1) ATE522515T1 (de)
AU (1) AU2009242095A1 (de)
CA (1) CA2722986A1 (de)
DK (1) DK2271638T3 (de)
MX (1) MX2010011498A (de)
WO (1) WO2009133110A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010011724A (es) 2008-04-29 2010-11-30 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
JP2011519839A (ja) * 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
SG193992A1 (en) 2011-04-19 2013-11-29 Integrative Res Lab Sweden Ab Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
JP6311025B2 (ja) * 2013-12-12 2018-04-11 バイオ−ファーム ソリューションズ カンパニー リミテッド 痛症を治療又は緩和するためのスルファメート誘導体化合物
CN106928147A (zh) * 2017-03-14 2017-07-07 华东师范大学 三环二萜类似物及其制备方法、及其在制备抗前列腺癌药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3058980A (en) * 1962-10-16 Substitution products of benzo-
US2906757A (en) * 1959-09-29 Their preparation
DE1110175B (de) * 1957-01-08 1961-07-06 Rhone Poulenc Sa Verfahren zur Herstellung von Benzodioxanderivaten
US3851062A (en) * 1973-08-01 1974-11-26 Minnesota Mining & Mfg Method of suppressing weight gain
US4056540A (en) * 1974-01-01 1977-11-01 Bristol-Myers Company 4-Phenyl-1,3-benzodioxans
US5189171A (en) * 1991-06-21 1993-02-23 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5166367A (en) * 1991-06-21 1992-11-24 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5126366A (en) * 1991-06-21 1992-06-30 American Home Products Corporation Aminophenoxyalkyl derivatives of benzodioxan
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5235055A (en) * 1992-09-02 1993-08-10 American Home Products Corporation Antipsychotic quinoline derivatives of benzodioxanmethylamine
US5245051A (en) * 1992-09-03 1993-09-14 American Home Products Corporation Antipsychotic chroman derivatives of benzodioxanmethylamine
WO1996038435A1 (en) * 1995-05-30 1996-12-05 Abbott Laboratories Dopamine agonists
US5663194A (en) * 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
AR004229A1 (es) * 1995-11-06 1998-11-04 Wyeth Corp Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos
FR2791675B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
GB0007376D0 (en) * 2000-03-28 2000-05-17 Knoll Ag Therapeutic agents
BR0213094A (pt) 2001-10-04 2004-10-13 Wyeth Corp Derivados de cromano como ligandos de 5-hidroxi-triptamina-6
AU2004283313A1 (en) * 2003-10-24 2005-05-06 Exelixis, Inc. TAO kinase modulators and methods of use
ATE458727T1 (de) 2004-05-05 2010-03-15 Hoffmann La Roche Zur modulation des 5-ht6-rezeptors, des 5-ht2a- rezeptors oder beider rezeptoren geeignete arylsulfonylbenzodioxane
DE602005017784D1 (de) * 2004-06-08 2009-12-31 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine als modulatoren der dopamin- und serotoninneurotransmission
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
BRPI0610046A2 (pt) 2005-04-22 2010-05-25 Wyeth Corp derivados de benzodioxano e benzodioxolano e usos destes
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
AR060493A1 (es) * 2006-04-18 2008-06-18 Wyeth Corp Derivados de benzodioxano y benzodioxolano. procesos de obtencion.
AU2007253814A1 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
JP2011519839A (ja) * 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
MX2010011724A (es) * 2008-04-29 2010-11-30 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.

Also Published As

Publication number Publication date
US20110112065A1 (en) 2011-05-12
US8492372B2 (en) 2013-07-23
MX2010011498A (es) 2010-11-12
DK2271638T3 (da) 2011-11-28
JP5548853B2 (ja) 2014-07-16
EP2271638A1 (de) 2011-01-12
CN102015674B (zh) 2014-10-29
CN102015674A (zh) 2011-04-13
EP2271638B1 (de) 2011-08-31
AU2009242095A1 (en) 2009-11-05
JP2011518859A (ja) 2011-06-30
CA2722986A1 (en) 2009-11-05
WO2009133110A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
CY1117143T1 (el) Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
MA32383B1 (fr) DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
MA32508B1 (fr) Composes organiques
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
MX2010008714A (es) Derivados de amida como moduladores alostericos positivos y metodos de uso de los mismos.
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
JO3425B1 (ar) مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
DK2078010T3 (da) Polycyklisk heteroaryl-substituerede triazoler, der er anvendelige som axl-hæmmere
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
UA110600C2 (uk) Спосіб отримання захищених похідних l-аланіну
EA201170772A1 (ru) Органические соединения
GEP20227397B (en) Inhibitors of influenza viruses replication
BR112012011328A2 (pt) inibidores de akt
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
IN2012DN05125A (de)
ATE499367T1 (de) 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
ATE522515T1 (de) Modulatoren der dopamin-neurotransmission

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2271638

Country of ref document: EP